AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05575063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Healon EndoCoat
Description: Ophthalmic Viscoelastic device
Study NCT05096884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
Study NCT05203913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
Study NCT06013969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab intravenous (i.v.) infusion
Study NCT05810870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1611
Description: MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.
Study NCT05810870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
Study NCT05203913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
Study NCT06146062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells (MSC)
Description: 3 injections one week apart
Study NCT06146062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 injections one week apart
Study NCT06001749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A tryptamine derivative, capsule, taken orally.
Study NCT05811949 — intervention group
Intervention type: DRUG
Intervention: Dimethyl Fumarate 240 MG [Tecfidera]
Description: DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
Study NCT04905407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Tamibarotene tablets will be administered per dose and schedule specified in the arm.
Study NCT04905407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered per dose and schedule specified in the arm.
Study NCT04905407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax tablets will be administered per dose and schedule specified in the arm.
Study NCT04905407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine injection will be administered per dose and schedule specified in the arm.
Study NCT04905407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine injection will be administered per dose and schedule specified in the arm.
Study NCT04441515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipod with music
Description: music of patient's preference provided 2 hours daily
Study NCT04441515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ipod with books to listen
Description: 2 hours of daily listening to books
Study NCT04441515 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ipod only with usual care
Description: participants given device only
Study NCT06223269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin Xenotransplant
Description: realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area.
Study NCT06223269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft(ing)
Description: Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
Study NCT06193239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OWL-EVO1
Description: EVOC probe
Study NCT05515237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grade 2-5 CI Therapy + Sensory Components
Description: All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
Study NCT05559047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse novel CPAP mask
Description: Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
Study NCT05559047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips Respironics Nuance
Description: Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
Study NCT06228937 — intervention group
Intervention type: OTHER
Intervention: analysis of a sample of stool
Description: typing of the gut microbiota from a stool sample
Study NCT05402501 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention program Leef! met MS
Description: The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
Study NCT06361251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYONOVE (EC14_4osc)
Description: The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
Study NCT06361251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYONOVE (EC05osc)
Description: The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
Study NCT03804905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-cost Medications
Description: Patients will be connected to Trillium Health Partners outpatient pharmacy, and they will be given an information sheet with further details. The patients will get free access to diabetes, blood pressure and cholesterol medications and for glucose test strips. They can attend the pharmacy in person or arrange for home delivery.
Study NCT06405529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge
Description: During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto.
Study NCT05328622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aqueduct Contingency Management Platform
Description: All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care.
Study NCT05260242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disparities Conversation
Description: The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
Study NCT06571877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention with manipulation of the energy density
Description: Dietary intervention with manipulation of the energy density either during breakfast or during lunch
Study NCT06199778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: 1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers.
Study NCT06199778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
Study NCT06199778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube feeding
Description: The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
Study NCT06199778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reserpine
Description: Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.
Study NCT06199778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reserpine
Description: Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.
Study NCT06199778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
Study NCT06199778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
Study NCT05908760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 ReHaler
Description: The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
Study NCT05526170 — intervention group
Intervention type: DEVICE
Intervention: Devices for long-term monitoring of objective and subjective parameters of the body
Description: Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
Study NCT05713487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventive treatment group
Description: each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
Study NCT05536791 — intervention group
Intervention type: DRUG
Intervention: Dabigatran Etexilate (DE)
Description: Dabigatran Etexilate (DE)
Study NCT05175157 — intervention group
Intervention type: OTHER
Intervention: Gut Fellings questionnaire
Description: Answer the Gut Fellings questionnaire
Study NCT06525012 — intervention group
Intervention type: OTHER
Intervention: Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin
Description: During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.
Study NCT05661409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated.
Study NCT05203913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
Study NCT05203913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
Study NCT04647734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week
Study NCT04647734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: standard care after discharge from hospital (control group)
Study NCT06317597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
Study NCT06388031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg.
Study NCT05434351 — intervention group
Intervention type: OTHER
Intervention: vaginal dehydroepiandrosterone
Description: the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
Study NCT05554172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Participants will receive vagal nerve stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
Study NCT05554172 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants will receive sham stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
Study NCT04969354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
Study NCT06397222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sin-Bev-SIRT
Description: Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study NCT05306197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Feedback Training
Description: Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
Study NCT05306197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
Study NCT05306197 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Contingent Feedback Training
Description: Participants listen to a musical track they chose with no operant conditioning.
Study NCT05661409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated.
Study NCT05661409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
Study NCT05815173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.